SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Angiotech Pharmaceuticals Inc, et al. – ‘F-10’ on 10/24/06 – EX-5.1

On:  Tuesday, 10/24/06, at 9:50pm ET   ·   As of:  10/25/06   ·   Accession #:  1193125-6-214006   ·   File #s:  333-138185, -01, -02, -03, -04, -05, -06, -07, -08, -09, -10, -11, -12, -13, -14, -15, -16, -17, -18, -19, -20, -21, -22, -23, -24, -25, -26, -27, -28, -29, -30, -31, -32, -33, -34

Previous ‘F-10’:  ‘F-10/A’ on 9/25/03   ·   Next:  ‘F-10/A’ on 12/13/06   ·   Latest:  ‘F-10/A’ on 4/2/07

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

10/25/06  Angiotech Pharmaceuticals Inc     F-10                  67:7.8M                                   RR Donnelley/FA
          Angiotech Capital, LLC
          Angiotech Pharmaceuticals (US), Inc.
          3091798 Nova Scotia Co
          3091797 Nova Scotia Co
          B.G. Sulzle, Inc.
          Crimson Cardinal Capital, Inc.
          Manan Medical Products, Inc.
          NeuColl, Inc.
          3129539 Nova Scotia Co
          3129540 Nova Scotia Co
          3129541 Nova Scotia Co
          3132933 Nova Scotia Co
          3132935 Nova Scotia Co
          0741693 B.C. Ltd.
          0761717 B.C. Ltd.
          3091796 Nova Scotia Co
          3091799 Nova Scotia Co
          3129537 Nova Scotia Co
          3129538 Nova Scotia Co
          3132934 Nova Scotia Co
          3132936 Nova Scotia Co
          Afmedica, Inc.
          American Medical Instruments Holdings, Inc.
          American Medical Instruments, Inc.
          Angiotech BioCoatings Corp.
          Angiotech International Holdings, Corp.
          Angiotech Investment Partnership
          Medical Device Technologies, Inc.
          Point Technologies, Inc.
          Quill Medical, Inc.
          Surgical Specialties Corp.
          Surgical Specialties Puerto Rico, Inc.
          Surgical Specialties UK Holdings Ltd
          Tercentenary Holdings, Corp.

Registration Statement of a Foreign Private Issuer (Not Effective Immediately)   —   Form F-10
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: F-10        Registration Statement of a Foreign Private Issuer  HTML   1.14M 
                          (Not Effective Immediately)                            
 2: EX-3.1      Articles of Angiotech Pharmaceuticals, Inc.         HTML    331K 
11: EX-3.10     Memorandum and Articles of Association              HTML    195K 
12: EX-3.11     Memorandum and Articles of Association              HTML    180K 
13: EX-3.12     Memorandum and Articles of Association              HTML    180K 
14: EX-3.13     Memorandum and Articles of Association              HTML    180K 
15: EX-3.14     Memorandum and Articles of Association              HTML    180K 
16: EX-3.15     Order of Amalgamation                               HTML    201K 
17: EX-3.16     Partnership Agreement                               HTML    184K 
18: EX-3.17     Order of Amalgamation                               HTML    200K 
19: EX-3.18     Certificate of Merger of Afmedica, Inc.             HTML     38K 
20: EX-3.19     Bylaws of Afmedica, Inc.                            HTML    127K 
 3: EX-3.2      Articles of 0741693 B.C. Ltd.                       HTML    252K 
21: EX-3.20     Certificate of Incorporation                        HTML     41K 
22: EX-3.21     Amended and Restated Bylaws                         HTML     65K 
23: EX-3.22     Certificate of Incorporation                        HTML     40K 
24: EX-3.23     Bylaws of American Medical Instruments, Inc.        HTML     60K 
25: EX-3.24     Certificate of Incorporation                        HTML     95K 
26: EX-3.25     Bylaws of Angiotech Biocoatings Corp.               HTML     52K 
27: EX-3.26     Articles of Organization                            HTML     32K 
28: EX-3.27     Operating Agreement                                 HTML     62K 
29: EX-3.28     Amended and Restated Articles of Incorporation      HTML     45K 
30: EX-3.29     Bylaws of Angiotech Pharmaceuticals (Us), Inc.      HTML     62K 
 4: EX-3.3      Articles of 0761717 B.C. Ltd.                       HTML    283K 
31: EX-3.30     Certificate of Incorporation                        HTML     42K 
32: EX-3.31     Bylaws of B.G. Sulzle, Inc.                         HTML     59K 
33: EX-3.32     Articles of Organization                            HTML     43K 
34: EX-3.33     Operating Agreement                                 HTML    118K 
35: EX-3.34     Certificate of Incorporation                        HTML     42K 
36: EX-3.35     Bylaws of Manan Medical Products, Inc.              HTML     60K 
37: EX-3.36     Certificate of Incorporation                        HTML     40K 
38: EX-3.37     Bylaws of Medical Device Technologies, Inc.         HTML     59K 
39: EX-3.38     Certificate of Merger                               HTML     38K 
40: EX-3.39     Bylaws of of Neucoll, Inc.                          HTML     64K 
 5: EX-3.4      Memorandum and Articles of Association              HTML    180K 
41: EX-3.40     Articles of Incorporation                           HTML     36K 
42: EX-3.41     Bylaws of Point Technologies, Inc.                  HTML     50K 
43: EX-3.42     Certificate of Incorporation                        HTML     42K 
44: EX-3.43     Bylaws of Surgical Specialties Corporation          HTML     60K 
45: EX-3.44     Certificate of Incorporation                        HTML     59K 
46: EX-3.45     Bylaws of Quill Medical, Inc.                       HTML    120K 
47: EX-3.46     Certificate of Incorporation                        HTML     43K 
48: EX-3.47     Amended and Restated Bylaws                         HTML     61K 
49: EX-3.48     Memorandum and Amended Articles of Association      HTML     81K 
50: EX-3.49     Memorandum & Articles of Association                HTML    177K 
 6: EX-3.5      Memorandum and Articles of Association              HTML    180K 
51: EX-3.50     Memorandum & Articles of Association                HTML    177K 
 7: EX-3.6      Memorandum and Articles of Association              HTML    180K 
 8: EX-3.7      Memorandum and Articles of Association              HTML    195K 
 9: EX-3.8      Memorandum and Articles of Association              HTML    195K 
10: EX-3.9      Memorandum and Articles of Association              HTML    195K 
52: EX-4.1      Indenture                                           HTML    658K 
53: EX-4.2      Supplemental Indenture                              HTML     42K 
54: EX-5.1      Opinion of Sullivan & Cromwell LLP, Special Us      HTML     34K 
                          Counsel                                                
55: EX-5.2      Opinion of Irwin, White & Jennings, British         HTML     40K 
                          Columbia Counsel                                       
56: EX-5.3      Opinion of Stewart McKelvey, Nova Scotia Counsel    HTML     43K 
57: EX-5.4      Opinion of Lionel Sawyer & Collins, Nevada Counsel  HTML     33K 
58: EX-5.5      Opinion of Heller Ehrman White & McAuliffe LLP,     HTML     57K 
                          Washington Counsel                                     
59: EX-5.6      Opinion of Faegre & Benson LLP, Colorado Counsel    HTML     42K 
60: EX-5.7      Opinion of McConnell Valdes, Puerto Rico Counsel    HTML     41K 
61: EX-5.8      Opinion of Herbert Smith LLP, England & Wales       HTML     74K 
62: EX-23.1     Consent of Ernst & Young LLP                        HTML     29K 
63: EX-23.2     Consent of Pricewaterhousecoopers LLP               HTML     27K 
64: EX-23.3     Consent of Hughes Pittman and Gupton LLP            HTML     28K 
65: EX-25.1     Statement of Eligibility of the Trustee on Form     HTML     67K 
                          T-1                                                    
66: EX-99.1     Letter of Transmittal                               HTML    114K 
67: EX-99.2     Notice of Guaranteed Delivery                       HTML     38K 


EX-5.1   —   Opinion of Sullivan & Cromwell LLP, Special Us Counsel


This exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



  Opinion of Sullivan & Cromwell LLP, Special US counsel  

Exhibit 5.1

LOGO

October 24, 2006

Angiotech Pharmaceuticals, Inc.,

1618 Station Street,

Vancouver, BC Canada V6A 1B6.

Ladies and Gentlemen:

In connection with the registration under the Securities Act of 1933 (the “Securities Act”) of (a) $250,000,000 principal amount of 7.75% Senior Subordinated Notes due 2014 (the “Notes”) of Angiotech Pharmaceuticals, Inc., a corporation organized under the Business Corporations Act of British Columbia, Canada (the “Company”), to be issued in exchange for the Company’s outstanding 7.75% Senior Notes due 2014 pursuant to an Indenture, dated as of March 23, 2006 (the “Indenture”), among the Company, the subsidiaries of the Company party thereto (collectively, the “Guarantors”) and Wells Fargo Bank, N.A., as trustee (the “Trustee”), and (b) the Guarantees (the “Guarantees”) of each of the Guarantors endorsed upon the Notes, we, as your special U.S. counsel, have examined such corporate records, certificates and other documents, and such questions of law, as we have considered necessary or appropriate for the purposes of this opinion.

Upon the basis of such examination, we advise you that, in our opinion, when the Company’s combined registration statement on Forms F-10, F-4 and S-4 relating to the Notes and the Guarantees (the “Registration Statement”) has become effective under the Securities Act, the terms of the Notes and the Guarantees and of their issuance have been duly established in conformity with the Indenture so as not to violate any applicable law or result in a default under or breach of any agreement or instrument binding upon the Company or the Guarantors, respectively and so as to comply with any requirement or restriction imposed by any court or governmental body having jurisdiction over the Company and the Guarantors, respectively, and the Notes and Guarantees have been duly executed, delivered and authenticated in accordance with the Indenture and issued as contemplated in the Registration Statement, the Notes and the Guarantees will constitute valid and legally binding obligations of the Company and the Guarantors, respectively, subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar laws of general applicability relating to or affecting creditors’ rights and to general equity principles.

The foregoing opinion is limited to the Federal laws of the United States, the laws of the State of New York and the General Corporation Law of the State of Delaware and we are expressing no opinion as to the effect of the laws of any other jurisdiction.

We have relied as to certain factual matters on information obtained from public officials, officers of the Company and the Guarantors and other sources believed by us to be responsible, and we have assumed that the Indenture has been duly authorized, executed and delivered by each of the parties thereto (other than those Guarantors listed on Schedule A hereto), the Notes will be duly authorized by the Company, the Guarantees will be duly authorized by the Guarantors (other than those Guarantors listed on Schedule A hereto), that the Company and the Guarantors (other than those Guarantors listed on Schedule A hereto) have been duly organized and are existing corporations in good standing under the laws of their respective jurisdictions of organizations and that the Notes and the Guarantees will constitute valid and legally binding obligations of the Company and the Guarantors (other than those Guarantors listed on Schedule A hereto) under the laws of their respective jurisdictions of organization, subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar laws of general applicability relating to or affecting creditors’ rights and to general equity principles, assumptions which we have not independent verified.

We hereby consent to the filing of this opinion as an exhibit to the Registration Statement and to the reference to us under the heading “Validity of the Securities” in the prospectus forming a part of the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act.

Very truly yours,

/s/ Sullivan & Cromwell LLP


Schedule A

 

Afmedica, Inc.

  

American Medical Instruments Holdings, Inc.

  

American Medical Instruments, Inc.

  

Angiotech BioCoatings Corp.

  

B.G. Sulzle, Inc.

  

Manan Medical Products, Inc.

  

Medical Device Technologies, Inc.

  

NeuColl, Inc.

  

Quill Medical, Inc.

  

Surgical Specialties Corporation

  

 

-2-


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘F-10’ Filing    Date    Other Filings
Filed as of:10/25/066-K,  F-X
Filed on:10/24/066-K
3/23/06
 List all Filings 
Top
Filing Submission 0001193125-06-214006   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Fri., Mar. 29, 8:18:04.1am ET